Merck (MRK) Gains As Market Dips: What You Should Know
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Qualcomm, Merck, Rockwell Automation And A Real Estate Stock On CNBC's ‘Final Trades'
The Big 3: JPM, DHR, MRK
MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets
Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
Merck's Oncology Engine Is Still Accelerating
Merck's bowel disease drug meets main goal in late-stage trial
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Protillion Biosciences Announces Drug Discovery Collaboration with Merck
Merck: Buy The Dip On This Dividend Growth Pharma Leader
3 Dividend Stocks to Hold for the Long Haul
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Merck Animal Health to Acquire TARGAN
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
Dividend ETFs: SCHD Boasts a Larger Dividend Yield, While VIG Has Lower Fees
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors